MedTrace Logo

Molecular Breast Imaging: A Novel Technology for Detection of Malignant Breast Lesions

NCT01004666 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2013-01-04

No results posted yet for this study

Summary

Detection of breast cancer as early as possible is an ongoing imaging challenge.The purpose of the current study is to assess the clinical performance of the new scintigraphic technology, a dedicated breast gamma camera composed by the new generation of CZT detectors,for assessment of breast pathology specifically in women where current imaging techniques, mainly mammography are suboptimal. These cohort are patients with dense breast tissue and patients who are at high risk for breast cancer by a combination of other metrics, including family history and genetic testing. BRCA (breast cancer susceptibility gene), is particularly a relevant health problem among Ashkenazi Jews in Israel.

Conditions

  • Small Breast Lesions
  • Dense Breast Tissue
  • Discrepancy With Clinical Examination
  • Equivocal Mammographic, Sonographic or MRI Lesion

Sponsors & Collaborators

  • Tel-Aviv Sourasky Medical Center

    lead OTHER_GOV

Principal Investigators

  • Einat Even-Sapir, MD, PhD · Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Eligibility

Min Age
25 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2014-10-31
Completion
2015-10-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01004666 on ClinicalTrials.gov